Sglt 2i CKD Farxiga denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for sglt2i ckd farxiga are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Farxiga (dapagliflozin) as Duplicate Therapy for CKD — and How to Appeal

Farxiga (dapagliflozin) is an SGLT2 inhibitor with a distinct FDA-approved indication for chronic kidney disease (CKD) in adults. A "duplicate therapy" denial from Cigna typically means the plan's system flagged that you are already taking another drug in the same pharmacological class — most commonly another SGLT2 inhibitor, or occasionally a medication Cigna's algorithm classifies as therapeutically equivalent for CKD. This denial is frequently wrong on the clinical merits, because not all SGLT2 inhibitors carry the same FDA-approved CKD indication.

### Why This Denial Is Commonly Overturned

FDA approvals are indication-specific. If your prescriber chose dapagliflozin specifically because of its FDA-approved CKD indication and the other agent on your profile does not share that indication, the therapeutic duplication premise is factually incorrect. Demonstrating that distinction — in writing, with references to the respective FDA labels — is often sufficient to overturn the denial at the internal-appeal stage.

Even when both agents do share a class, a prescriber may have a documented clinical reason for the combination. Your appeal should address this directly.

### Federal Appeal Framework

• Internal appeal: File under your plan's ERISA §503 (employer plan) or ACA internal-review rights. Deadline is typically on the denial letter — often 180 days.
• External review (ACA §2719): If internally denied, an independent review organization reviews the case. File within approximately four months of the final internal denial. The external decision is binding on Cigna.
• Expedited option: Available when standard timelines would seriously jeopardize health — decisions typically within 72 hours.

### Concrete Appeal Steps and Timeline

1. Obtain the denial letter and identify the specific drug Cigna listed as duplicative. 2. Pull the FDA-approved prescribing information for Farxiga and for the other agent. Compare the approved indications precisely — this is your primary exhibit. 3. Have your prescriber document in a medical-necessity letter: (a) the specific FDA-approved indication for which dapagliflozin was prescribed, (b) why the other agent does not fulfill that indication, and (c) if relevant, the clinical rationale for concurrent use. 4. File the internal appeal with both FDA labels attached as exhibits. 5. Track the internal-appeal deadline and the external-review window.

### Documentation to Gather

• FDA prescribing labels: Printed current labels for Farxiga and the agent Cigna identified as duplicative, with the indications section highlighted.
• CKD diagnosis confirmation: Nephrologist or primary-care notes establishing the CKD diagnosis, stage, and relevant lab trend (without specific numeric thresholds — your physician will cite the appropriate values from the current clinical guidelines).
• Prior treatment history: Records of other CKD-relevant therapies tried, with dates and outcomes.
• Prescriber letter: A signed letter explaining the clinical distinction between the two agents and the medical necessity of dapagliflozin specifically.

### Criteria-Mapping Structure

For each basis Cigna cited for duplicate therapy, provide a written response that either (a) refutes the therapeutic equivalence with FDA label evidence, or (b) documents the clinical necessity of concurrent use. Leave no criterion unanswered.